These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34449177)

  • 1. Patterns of drug therapy, glycemic control, and predictors of escalation - non-escalation of treatment among diabetes outpatients at a tertiary care center.
    Atal S; Joshi R; Misra S; Fatima Z; Sharma S; Balakrishnan S; Singh P
    J Basic Clin Physiol Pharmacol; 2022 Nov; 33(6):803-814. PubMed ID: 34449177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period.
    Mansour AA; Alibrahim NTY; Alidrisi HA; Alhamza AH; Almomin AM; Zaboon IA; Kadhim MB; Hussein RN; Nwayyir HA; Mohammed AG; Al-Waeli DKJ; Hussein IH;
    Diabetes Metab Syndr; 2020; 14(3):265-272. PubMed ID: 32272433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
    Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
    Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The status of glycemic control: A cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China.
    Bi Y; Zhu D; Cheng J; Zhu Y; Xu N; Cui S; Li W; Cheng X; Wang F; Hu Y; Shen S; Weng J
    Clin Ther; 2010 May; 32(5):973-83. PubMed ID: 20685506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications.
    Huri HZ; Lim LP; Lim SK
    Drug Des Devel Ther; 2015; 9():4355-71. PubMed ID: 26300627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
    Jiang G; Luk AO; Tam CHT; Lau ES; Ozaki R; Chow EYK; Kong APS; Lim CKP; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JYY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung SKS; Cheng YL; Chow CC; Pearson ER; So WY; Chan JCN; Ma RCW; ;
    PLoS Med; 2020 Jul; 17(7):e1003209. PubMed ID: 32722720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of patient education on KAP, medication adherence and therapeutic outcomes of metformin versus insulin therapy in patients with gestational diabetes: A Hospital based pilot study in South India.
    Krishnakumar S; Govindarajulu Y; Vishwanath U; Nagasubramanian VR; Palani T
    Diabetes Metab Syndr; 2020; 14(5):1379-1383. PubMed ID: 32755838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication Management Program: Adherence, Disease-related Knowledge, Health-related Quality of Life, and Glycemic Control for Type 2 Diabetes Mellitus.
    Nazir SUR; Hassali MA; Saleem F; Haque N
    Altern Ther Health Med; 2020 Jul; 26(S2):4-10. PubMed ID: 31634877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of HbA1c levels in patients initiating metformin.
    Martono DP; Hak E; Lambers Heerspink H; Wilffert B; Denig P
    Curr Med Res Opin; 2016 Dec; 32(12):2021-2028. PubMed ID: 27552675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting postprandial blood sugar over fasting blood sugar: A clinic based comparative study.
    Herath HMM; Weerarathna TP; Fonseka CL; Vidanagamage AS
    Diabetes Metab Syndr; 2017; 11(2):133-136. PubMed ID: 27746068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of glycemic control and related factors among outpatients with type 2 diabetes at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a cross-sectional study.
    Abera RG; Demesse ES; Boko WD
    BMC Endocr Disord; 2022 Mar; 22(1):54. PubMed ID: 35249547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for clinical predictors of good glycemic control in patients starting or intensifying oral hypoglycemic pharmacological therapy: A multicenter prospective cohort study.
    Ren Q; Ji LN; Lu JM; Li YF; Li QM; Lin SS; Lv XF; Wang L; Xu Y; Guo XH; Guo QY; Ma L; Du J; Chen YL; Zhao CL; Zhang QL; She QM; Jiao XM; Lu MH; Sun XM; Gao Y; Zhang J
    J Diabetes Complications; 2020 Feb; 34(2):107464. PubMed ID: 31771933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.